These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

434 related items for PubMed ID: 15739020

  • 1. A new look at the prognostic value of the estrogen, progesterone and epidermal growth factor receptors in breast cancer tissue.
    Skasko E, Paszko Z, Mazur S.
    Neoplasma; 2005; 52(1):10-7. PubMed ID: 15739020
    [Abstract] [Full Text] [Related]

  • 2. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.
    J Natl Cancer Inst; 2005 Sep 07; 97(17):1254-61. PubMed ID: 16145046
    [Abstract] [Full Text] [Related]

  • 3. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
    Derin D, Eralp Y, Ozluk Y, Yavuz E, Guney N, Saip P, Igci A, Ozmen V, Kücücük S, Aslay I, Aydiner A, Topuz E.
    Cancer Invest; 2008 Aug 07; 26(7):671-9. PubMed ID: 18608215
    [Abstract] [Full Text] [Related]

  • 4. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Apr 12; 7():63. PubMed ID: 17430582
    [Abstract] [Full Text] [Related]

  • 5. The importance of prognostic factors in premenopausal women with breast cancer.
    Finek J, Holubec L, Topolcan O, Elgrova L, Skalova A, Pecen L.
    Anticancer Res; 2007 Apr 12; 27(4A):1893-6. PubMed ID: 17649790
    [Abstract] [Full Text] [Related]

  • 6. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.
    Charafe-Jauffret E, Tarpin C, Bardou VJ, Bertucci F, Ginestier C, Braud AC, Puig B, Geneix J, Hassoun J, Birnbaum D, Jacquemier J, Viens P.
    J Pathol; 2004 Mar 12; 202(3):265-73. PubMed ID: 14991891
    [Abstract] [Full Text] [Related]

  • 7. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
    Fan Y, Guan Y, Zhao WH, Li Q, Xu BH.
    Zhonghua Zhong Liu Za Zhi; 2008 Dec 12; 30(12):917-20. PubMed ID: 19173993
    [Abstract] [Full Text] [Related]

  • 8. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information.
    Biesterfeld S, Schröder W, Steinhagen G, Koch R, Veuskens U, Schmitz FJ, Handt S, Böcking A.
    Anticancer Res; 1997 Dec 12; 17(6D):4723-9. PubMed ID: 9494596
    [Abstract] [Full Text] [Related]

  • 9. [Long-term prognostic role of steroid receptors in cancer of the breast].
    Broët P, Pichon MF, Magdelenat H, Delarue JC, Spyratos F, Basuyau JP, Saez S, Rallet A, Courrière P, Millon R, Asselain B.
    Bull Cancer; 1998 Apr 12; 85(4):347-52. PubMed ID: 9752299
    [Abstract] [Full Text] [Related]

  • 10. Prognostic significance of the combination of biological parameters in breast cancer.
    Tsutsui S, Ohno S, Murakami S, Kataoka A, Kinoshita J, Hachitanda Y.
    Surg Today; 2003 Apr 12; 33(2):151-4. PubMed ID: 12616383
    [Abstract] [Full Text] [Related]

  • 11. Prognostic significance of intra-tumoral estradiol level in breast cancer patients.
    Miyoshi Y, Akazawa K, Kamigaki S, Ueda S, Yanagisawa T, Inoue T, Yamamura J, Taguchi T, Tamaki Y, Noguchi S.
    Cancer Lett; 2004 Dec 08; 216(1):115-21. PubMed ID: 15500955
    [Abstract] [Full Text] [Related]

  • 12. [Expression of ER, PR and cyclin D1 in breast infiltrating ductal carcinoma and their clinicopathological significance].
    Wang ZB, Zhao P, Liu M, Li XH.
    Zhonghua Yi Xue Za Zhi; 2005 Mar 02; 85(8):514-7. PubMed ID: 15949328
    [Abstract] [Full Text] [Related]

  • 13. Correlation of the EGF-receptor with cell kinetic and classical prognostic factors in breast cancer.
    Oehler MK, Rehn M, Kristen P, Sütterlin M, Caffier H.
    Anticancer Res; 1997 Mar 02; 17(4B):3137-40. PubMed ID: 9329620
    [Abstract] [Full Text] [Related]

  • 14. Prognostic markers in node-negative breast cancer: a prospective study.
    Kute TE, Russell GB, Zbieranski N, Long R, Johnston S, Williams H, Stackhouse C, Wilkins L, Evans I, Berry P, Rimmer K, Tucker E.
    Cytometry B Clin Cytom; 2004 May 02; 59(1):24-31. PubMed ID: 15108167
    [Abstract] [Full Text] [Related]

  • 15. Prognostic value of c-erbB2 expression in breast cancer.
    Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S.
    J Surg Oncol; 2002 Apr 02; 79(4):216-23. PubMed ID: 11920778
    [Abstract] [Full Text] [Related]

  • 16. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer.
    Eissa S, Khalifa A, el-Gharib A, Salah N, Mohamed MK.
    Anticancer Res; 1997 Apr 02; 17(4B):3091-7. PubMed ID: 9329609
    [Abstract] [Full Text] [Related]

  • 17. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients.
    Fischer-Colbrie J, Witt A, Heinzl H, Speiser P, Czerwenka K, Sevelda P, Zeillinger R.
    Anticancer Res; 1997 Apr 02; 17(1B):613-9. PubMed ID: 9066588
    [Abstract] [Full Text] [Related]

  • 18. Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer.
    Tsutsui S, Kataoka A, Ohno S, Murakami S, Kinoshita J, Hachitanda Y.
    Clin Cancer Res; 2002 Nov 02; 8(11):3454-60. PubMed ID: 12429634
    [Abstract] [Full Text] [Related]

  • 19. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.
    Ferrero-Poüs M, Hacène K, Bouchet C, Le Doussal V, Tubiana-Hulin M, Spyratos F.
    Clin Cancer Res; 2000 Dec 02; 6(12):4745-54. PubMed ID: 11156229
    [Abstract] [Full Text] [Related]

  • 20. [Impact of DNA image cytometry (ICM) parameter and established prognostic factors on disease free survival (DFS) and overall survival (OS) of node-negative breast cancer (NNBC) patients].
    Schlotter CM, Vogt U, Bosse U, Wassmann K.
    Zentralbl Gynakol; 2003 Sep 02; 125(9):368-74. PubMed ID: 14569519
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.